Search Results for:
-
Other News To Note
Ltd., of Taipei, Taiwan, submitted a new drug application (NDA) for the oral formulation of nemonoxacin with the Taiwan Food and Drug Administration (TFDA) and China Food and Drug Administration (CFDABioWorld Today | Friday, May 17, 2013 -
RuiYi, Genor Blaze Trail in China with JV for Rheumatoid Arthritis
Grayson expects RuiYi to file an investigational new drug application (IND) with the CFDA authorities within 18 to 26 monthsBy Dave Silver | BioWorld Today | Friday, May 17, 2013 -
Pharma: Other News To Note
received final approval from the FDA for its abbreviated new drug application for Zolmitriptan Tablets, 2.5 mg and 5 mgBioWorld Today | Thursday, May 16, 2013 -
Other News To Note
Arbor Pharmaceuticals Inc., of Atlanta, said the FDA approved its new drug application for Nymalize (nimodipine) oral solution...DSC127 is in two U.S. Phase III trials in diabetic foot ulcers, and Derma Sciences plans to submit a new drug application to the FDA following their completion. (See BioWorld Today, Feb. 7, 2013BioWorld Today | Wednesday, May 15, 2013 -
U.S. Decision Won't End Other Genentech-Sanofi Arbitration
The injunction also requires Ranbaxy to review and verify data submitted in past drug applications to the FDABio Perspectives | Tuesday, May 14, 2013 -
Clinic Roundup
Mirna filed its first investigational new drug application with the FDA for MRX34 earlier this yearBioWorld Today | Tuesday, May 14, 2013 -
Relypsa's Phase III Fully Enrolled; Top-Line Data Next
Based on its SPA for the pivotal study, the Redwood City, Calif.-based firm "feels really good" about submitting a new drug application (NDA) to the FDA on the heels of the Phase III trial, Klaerner saidBy Marie Powers | BioWorld Today | Tuesday, May 14, 2013 -
U.S. Decision Won't End Other Genentech-Sanofi Arbitration
The injunction also requires Ranbaxy to review and verify data submitted in past drug applications to the FDABy Mari Serebrov | BioWorld Today | Tuesday, May 14, 2013 -
Pharma: Other News To Note
Actavis Inc., of Parsippany, N.J., reported the FDA has accepted for filing its new drug application for a progestin-only transdermal contraceptive patch (Norethindrone Transdermal Delivery System) for use by women to prevent pregnancy...Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said the FDA granted priority review to its new drug application for simeprevir (TMC435), an NS3/4A protease inhibitor for once-daily administration with pegylated interferon andBioWorld Today | Tuesday, May 14, 2013 -
Beyond Kalbitor: Dyax Adds $30M for HAE Prophylactic
Dyax plans to file an investigational new drug application by the end of June and, pending acceptance by the FDA, will move into a Phase I study with healthy volunteers and then begin testing the drug in patientsBy Jennifer Boggs | BioWorld Today | Tuesday, May 14, 2013 -
Clinic Roundup
The company expects to report top-line results from the current study in late 2013 or early 2014 and to file a new drug application with the FDA in 2014. (See BioWorld Today, March 20, 2013BioWorld Today | Monday, May 13, 2013 -
From Boom to Bust: AFFY's Post-Recall Slide Continues
drug application, to the Osaka, Japan-based big pharmaBy Jennifer Boggs | BioWorld Today | Monday, May 13, 2013 -
FDA Submissions, Approvals & Other Actions: April 2013
IND = Investigational new drug application...NDA = New drug applicationBioWorld Insight | Monday, May 13, 2013 -
Remoxy on the Rocks: Durect, Pain Therapeutics Stocks Sink
Pain Therapeutics submitted the initial new drug application (NDA) for Remoxy, an extended-release oral formulation of oxycodone for the relief of moderate to severe pain, in June 2008 and received a CRL in December 2008By Catherine Shaffer | BioWorld Today | Monday, May 13, 2013 -
Other News To Note
Plandai Biotechnology Inc., of Seattle, said it formed Phyto Pharmacare Inc., a Delaware corporation to oversee all aspects of developing and marketing Phytofare extracts for pharmaceutical and drug applicationsBioWorld Today | Friday, May 10, 2013 -
Clinic Roundup
investigational new drug application in 2014 and begin Phase II studies for psoriasis and atopic dermatitis in the second half of 2014BioWorld Today | Thursday, May 9, 2013 -
Other News To Note
Earlier this month, Alimera resubmitted the new drug application for Iluvien, which has a PDUFA date of Oct. 17BioWorld Today | Thursday, May 9, 2013 -
Ovarian Trial 'MEKs' Big Year: Array Rolls Out Five Phase IIIs
Andrew Robbins, vice president of commercial operations for Array, noted that Novartis is scheduled to commence the NRAS melanoma trial "momentarily," and its data would be filed as a registration study, so that the ovarian trial's results would be part of a supplemental new drug application, if all goes wellBy Randy Osborne | BioWorld Today | Wednesday, May 8, 2013 -
Tufts Study: More Cancer Drugs Succeeding in the Clinic
However, cancer drugs that filed for regulatory approval mostly succeeded, with 92 percent that submitted a new drug application or biologics license application gaining the FDA's endorsementBy Marie Powers | BioWorld Today | Wednesday, May 8, 2013 -
Arrowhead Bolsters Balance Sheet, Adds $36M for Pipeline
Arrowhead expects to submit an investigational new drug application this quarter, with dosing in healthy volunteers expected to start in the third quarter...Proceeds will be used to fund ongoing pre-investigational new drug application studies for lead compound NPT002 and to advance fusion proteins for treating neurodegenerative conditions, including Alzheimer's, Parkinson's and Huntington's diseasesBy Jennifer Boggs | BioWorld Today | Tuesday, May 7, 2013
Category
Current Filters
- xdrug application
Related Keywords
Categories
- x BioWorld Today (7425)
- x BioWorld Insight (561)
- x BioWorld International (478)
- x Bio Perspectives (114)
- x State of the Industry Report (45)
- x BioWorld Snapshots (16)
- x Top 25 Drug Report (12)
- x BioWorld Genomics Review (12)
- x Biotech Innovations (11)
- x RNAi Report (2)
- x Market-Leading Biotech Drugs (2)
- x Executive Compensation Report (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.